DOI:
10.1055/s-00000129
Kardiologie up2date
LinksClose Window
References
Raal FJ, Stein EA, Dufour R et al.
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.
Lancet 2015;
385: 331-340
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.